Cadrenal Therapeutics, Inc. (CVKD)

Cadrenal Therapeutics will go public soon, but the exact IPO date is still unknown.
IPO Price
$5.00
Shares Offered
2,000,000
Deal Size
$10,000,000
Chart not available yet
Data will show when the stock starts trading.
Market Cap 55.58M
Revenue (ttm) n/a
Net Income (ttm) -678,788
Shares Out 11.12M
EPS (ttm) -0.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About CVKD

Cadrenal Therapeutics is focused on developing tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease, or ESRD, and atrial fibrillation (irregular heartbeat), or AFib. Most approved drugs, including warfarin, the only FDA-approved Vitamin K antagonists, or VKAs, which is a prescribed drug for the treatment of thrombosis, are metabolized in the liver through a pathway known as the Cytochrome CYP450 system, or CYP450,... [Read more...]

Industry Health Care
Founded 2022
CEO Quang Pham
Employees 1
Stock Exchange NASDAQ
Ticker Symbol CVKD
Full Company Profile

News

Cadrenal Therapeutics IPO Registration Document (S-1)

Cadrenal Therapeutics has filed to go public with an IPO on the NASDAQ.

1 week ago - SEC